

Resource Summary Report

Generated by [dkNET](#) on Aug 1, 2026

Purified anti-human CD20 (Maxpar(R) Ready)

RRID:AB_2562816

Type: Antibody

Proper Citation

BioLegend Cat# 302343, RRID:AB_2562816

Antibody Information

URL: http://antibodyregistry.org/AB_2562816

Proper Citation: BioLegend Cat# 302343, RRID:AB_2562816

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF®

Antibody Name: Purified anti-human CD20 (Maxpar(R) Ready)

Description: This monoclonal targets CD20

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone 2H7

Antibody ID: AB_2562816

Vendor: BioLegend

Catalog Number: 302343

Record Creation Time: 20250820T043413+0000

Record Last Update: 20250820T192021+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD20 (Maxpar(R) Ready).

No alerts have been found for Purified anti-human CD20 (Maxpar(R) Ready).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gerassy-Vainberg S, et al. (2024) A personalized network framework reveals predictive axis of anti-TNF response across diseases. Cell reports. Medicine, 5(1), 101300.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell reports. Medicine, 4(3), 100939.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 185(5), 916.

Fox-Fisher I, et al. (2022) B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. Med (New York, N.Y.), 3(7), 468.

van Montfoort N, et al. (2018) NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines. Cell, 175(7), 1744.